After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of Ocular Therapeutix Inc is $1.23B. A total of 1.4 million shares were traded on the day, compared to an average of 1.11M shares.
In the most recent transaction, Dugel Pravin sold 21,475 shares of OCUL for 6.87 per share on Feb 24 ’25. After the transaction, the insider now owns 3,520,318 company shares. In a previous transaction on Feb 24 ’25, Heier Jeffrey S. sold 3,061 shares at 6.87 per share. OCUL shares that Chief Scientific Officer owns now total 265,998.
Among the insiders who sold shares, Kaiser Peter disposed of 3,009 shares on Feb 24 ’25 at a per-share price of $6.87. This resulted in the Chief Development Officer holding 210,078 shares of OCUL after the transaction. In another insider transaction, Nayak Sanjay sold 1,895 shares at $6.84 per share on Feb 24 ’25. Company shares held by the Chief Strategy Officer now total 283,485.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, OCUL has a high of $11.77 and a low of $4.06.
As of this writing, OCUL has an earnings estimate of -$0.28 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of -$0.25 per share and a lower estimate of -$0.3.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. OCUL’s latest balance sheet shows that the firm has $164.16M in Cash & Short Term Investments as of fiscal 2021. There were $58.98M in debt and $26.34M in liabilities at the time. Its Book Value Per Share was $2.00, while its Total Shareholder’s Equity was $88.00M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OCUL is Buy with a score of 4.90.
